lasix without prescription Clomid without prescription celexa Levitra without prescription buy Zyvox online Diflucan no prescription cipro without prescription Cialis Professional no prescription Fluoxetine Buy Citalopram No Prescription Flomax buy jelly Cialis online Buy Doxycycline Online


  Home | Contact Us | Login | Register

Share This...Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn

News

Q2x Initiative: Quture International + Quture Health (1)

THE BUSINESS CASE

I have rewritten this Note to try to answer the question of a potential investor in Quture Health asking “but what’s it worth?” Then, as I was doing the final edit yesterday, my son called to ask if I had read his email about the purchase of Truven Health by IBM Watson. So this Note is what I can relate about the value of the Q2x Initiative today in this exponentially exploding healthcare outcomes and paralytics market.

Investors, shareholders, analysts, “the Street,” and those building businesses usually look to the size of the market opportunity, share of the market, upside potential, charts and predictions. But real world business decisions by the experts who run them impress me more.

Read More

TRANSITIONING FROM PEER REVIEW TO HEALTH DATA SCIENCE (2)

Translating Academic Research into QualOptima Trigger Algorithms

Triggers as Signals

Isaac Kohane, M.D., Ph.D., Professor & Co-Director of the Center for Biomedical Informatics, Harvard Medical School, explains how health care is missing huge signals by not paying attention. He gives the example of two top hospitals in Boston which had an 18% increase in heart attacks. He likens it to flying a thousand 747’sd1 filled with patients into this mountain of heart attacks, illustrated in the graph below as published in “The Telltale Heart: Population-Based Surveillance Reveals an Association of Robecoxib and Celecoxib with Myocardial Infarction,” PLoS one, Issue 9 (Sept. 2007). Most dramatically, as Dr. Kohane points out in his presentation, Exponential Growth of Bad Medicine, at Exponential Medicine, “not only did no one ever notice it, we actually caused it by giving the drug Vioxx to our patients” (causing cardiotoxicity).

Read More

TRANSITIONING FROM PEER REVIEW TO HEALTH DATA SCIENCE (1)

c1

“Our customers and potential customers, as well as our investors and potential investors, need to understand the significance of Quture’s focus for QualOptima v1.3 – to install it on cloud servers with intense security and massive functionality as a data warehouse. Quture looks forward to announcing our successful completion of this major, demanding and expensive undertaking and sales and marketing that will flow when this installation is completed.”

Read More

PHENOTYPE RISK FACTORS

The first Note posted was about risk predictive factors, ranging from traditional factors, such as family history or race and ethnicity (which are “phenotype”) patient factors to novel genome and biomarker (“genotype”) factors. Quture’s method of establishing a library of traditional and novel risk factors relies upon a systematic medical literature review, incidence and prevalence analysis of claims databases, and proof of concept analytics in de-identified patient databases.

To understand where Quture is today and how we got to our QualOptima experiential learning platform, think back to 2010 – 2012 and our formal clinical trial at the University 1bof Miami, Miller School of Medicine and Jackson Memorial Hospital. With the leadership of Quture’s Associate Medical Director, Keith A. Candiotti, M.D., we first introduced our risk stratified analytics system to measure clinical performance and outcomes (see Success Stories: University of Miami Clinical Trial). One of the primary risk factors for post-operative nausea and vomiting (PONV) is gender-specific – being a female (a phenotype risk factor). Our data analytics can be used not only to measure performance and outcomes, but as an experiential learning platform to learn from clinical patient-specific experience. For example, the different reactions of men and women to the antiemetic drugs, from different pharmaceutical companies, administered in different combinations, sequencing, and dosages, can be studied to understand how to achieve optimal clinical performance and outcomes. And in our study, we even began with the female gender being more at risk than males.

Read More

PREDICTIVE MODELING FROM CLINICAL RISK FACTORS

At Quture, we have worked in measuring healthcare performance & outcomes since we sponsored the first Dialogues in Obstetrics at the Del Coronado back in the 1980’s. Our first customer in external peer review, Daughters of Charity (now Ascension Health) came to us in a predecessor company. That was back in the days when you handed a chart to a physician and asked him/her a paper record, gave them either a Dictaphone or pad of paper and asked: “Tell me what you think of the care in this case.” As the pioneer of external peer review, we matured that process to a structured and more objective process with a software

Read More
1px

Quture (QUTR) Announces Formation of QualVal Solutions Consulting Subsidiary

Quture’s Subsidiary for Consulting Services Bundled With Its QualOptima Product Will Support and Strengthen Sales of Software as a Service (SaaS) to Significantly Enhance Revenue

DAYTONA BEACH, FL–(Marketwired – Oct 1, 2013) – Quture International, Inc. (OTCQB: QUTR) today announced the formation of the new subsidiary QualVal Solutions (QualVal). QualVal will provide consulting services bundled with Quture’s QualOptima product for software as a service (SaaS). Potential hospital customers of QualOptima have requested Quture’s Founder, Landon Feazell, provide consulting expertise in transforming traditional peer review processes to performance measurement to meet and exceed regulatory compliance requirements. Quture’s initial customer focus is on hospitals and physician groups. Quture is also forming the consulting subsidiary to expand its customer base beyond providers to the total array of potential customers — healthcare law firms, health and medical malpractice insurance companies, medical device and equipment manufacturers, electronic medical record (EMR) companies, accountable care organizations (ACO’s), health maintenance organizations (HMO’s), health information exchanges (HIE’s), insurance exchanges, ambulatory surgery centers, employer group plans and health incentive companies, pharmaceutical, proteomics and nutraceutical companies, and large CPA and other consulting firms, and vendors of other technologies that strategically enhance Quture in the market. QualVal is anticipated to provide revenue positive, immediate impact on the Company’s bottom line, repeating the previous millions of dollars generated by the Founder’s consulting companies.

“Potential customers during initial sales efforts have asked Quture to provide our traditional consulting services to assist them in transitioning from peer review to performance and outcomes measurement,” said Landon Feazell, Chairman & CEO of Quture. “We also have extraordinary business opportunities for the QualOptima Connectivity & Analytics System with potential businesses other than healthcare providers that are immediate and lucrative. As Quture introduces its new technology to health care, with the inherent measured pace of early adoption, these other customers provide excellent technology demonstration opportunities as well as immediate revenue. They further allow us to file for new patents as we stage the publication of the results of the Clinical Trial at the University of Miami and Jackson Memorial Hospital, working with Dr. Keith Candiotti.”

One initial thrust of QualVal will be to support and enhance licensing the QualOptima Peer Review and Performance & Outcomes Measurement Application, required for hospitals to conduct Focused and Ongoing Professional Practice Evaluation (FPPE-OPPE). The unique capability of QualOptima to permit remote peer review of medical records by physician reviewers facilitates development of user peer panels or for hospitals and hospital systems to use Quture’s QualPRO expert physician panels. Quture intends the bundled services of QualVal to initially include contracts with medical device manufacturers that will provide revenue while giving Quture real world experiences to test the proctoring application to complete delivering electronic technology solutions to all requirements of FPPE-OPPE.

Healthcare data and users of these data have been limited almost exclusively to billing data. QualOptima introduces patient-specific scientific risk factors and clinical performance and outcomes data electronically collected from disparate databases through its transformative and disruptive technology on the InterSystems technology platform. Customers of Quture need not only this technology but the expertise and experience of QualVal to strategically know what clinical data to measure, where that data resides, the scientific algorithms to analyze these data and, and most importantly why to measure (measure what you value, value what you measure) and what to do with the information to improve the quality of care and reduce costs, while significantly improving revenue to the bottom-line.

“Hospitals have tons of data, often the wrong data and limited key performance indicators and strategies,” said Feazell. “Our customers need our expertise and experience, combined with our new software technology, to more rapidly and effectively meet compliance requirements and realize the power of electronically capturing the data and with analytics embedded in QualOptima. While much has been proposed and hundreds of millions of dollars have been spent on mining ‘big data,’ the immediate opportunities are to strategically mine data. Quture’s expertise for 35 plus years in clinical performance and outcomes analytics is our immediate business advantage.”

Another immediate focus of QualVal will be to consult with healthcare law firms engaged by their clients in qui tam/whistleblower and fraud & abuse cases, as well as firms engaged to proactively prevent costly rack audits while optimizing revenue from efficient and effective billing and practice management software. The QualOptima product is ideal to electronically capture and integrate clinical data in parallel with billing data for litigation analytics. The unstructured data capture and analytics of QualOptima’s technology completes the essential tools for litigators and healthcare attorneys for their clients.

QualVal intends to provide consulting services beyond these initial focuses to include optimal clinical processes with risk & fitness factors and performance and outcomes metrics, credentialing and proctoring physicians and clinical practitioners, complication (including hospital acquired conditions) and readmission reductions strategies, analysis of overuse, underuse and misuse, and external clinical auditing, metrics to accomplish strategic planning goals and objectives, and branding strategies to increase patient loyalty and satisfaction and wellness.

“I have been privileged to work with some of the most prominent and proven consultants in American health care, and we are now engaged in the process to recruit them to leadership roles in QualVal as principals,” added Feazell. “We are also continuing to explore relationships with other healthcare consulting organizations for strategic alliances. Quture anticipates a series of announcements as core consulting experts contract with QualVal and Quture, as well as announcing specific bundled sales already in negotiations. Quture is making this announcement in anticipation of launching our new website, with the services and solutions portions of the site describing our capabilities and services and to attract customers as well as licensing QualOptima.”

ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. (QUTR) is the proven and experienced clinical performance and outcomes analytics company in the United States. The vision of Quture is to connect all constituents in the global health and health care community to clinically and financially focused and sound data transformed through analytics to knowledge that empowers data-driven decisions for results-driven success. As an Application Partner of InterSystems Corporation, Quture’s technology for capturing, integrating and aggregating data on the InterSystems Enterprise platform is unequalled. The Company’s unique product QualOptima develops a second generation CLINICAL database implementing Quture’s core competence of clinical content with evidence-based metrics developed for more than 35 years. QualOptima empowers clinical performance enhancement to achieve optimal patient outcomes. Quture’s brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned to become the leading clinical knowledge company in the world. Quture International is a Nevada corporation trading under the symbol QUTR.

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.

Contact:

Mele Telitz
Director of Communications
(720) 561-9643
mele@quture.com

For Further Information
Infinity Advisors
Mark Kroeger
(239) 495-6125

Read More
1px

Therapeutic Solutions International, Inc. (TSOI) Announces Agreement With Quture International, Inc. (QUTR) for QualVal Services Implementing QualOptima Analytics

Quture’s QualOptima Analytics Technology Will Transform the International Capabilities of Therapeutic Solutions to Market and Measure the Performance & Outcomes of Its Devices to Treat Intractable Migraine, Headache and Other Conditions

OCEANSIDE, CA–(Marketwired – Oct 3, 2013) – Therapeutic Solutions International, Inc. (OTCQB: TSOI) today announced an agreement with Quture International, Inc. (OTCQB: QUTR), Daytona Beach, FL (QUTR), to implement QualOptima analytics software as a service (SaaS) for TSI, through its newly formed consulting subsidiary QualVal Solutions, LLC. TSI markets and sells dental appliances that treat intractable migraine headache pain with extraordinary clinical results in the international market. As TSI enters new markets in South America and Asia, and continues its marketing efforts throughout Europe and the Pacific Rim, Quture will use the QualOptima Analytics System to revolutionize marketing of these devices. Specific clinical metrics and algorithms embedded in the QualOptima software, will analyze available databases using targeted personalized risk factors. This data will identify optimal candidates for treatment with TSI’s Migran-X device by their neurologists and dentists. Quture’s remarkable intellectual property (IP) will then be applied to measure performance and outcomes of TSI’s Migran-X® devices in patients to continuously monitor patient experience and clinical effectiveness. As TSI and Quture target country-specific markets, they intend to calculate financial projections for new revenue streams to TSI and Quture.

As TSI potentially expands into other medical device manufacturing and distribution, extensive databases available to Quture will be mined, again for marketing and outcomes measurement, as well as to potentially monitor patient experience and clinical effectiveness.

“We are excited about this opportunity, working with Quture, to increase our sales through more targeted marketing efforts and to better monitor and analyze clinical outcomes,” said Tim Dixon, Chairman & CEO of TSI. “Therapeutic Solutions markets an extraordinary FDA cleared (510(k)) dental appliance approved for the prevention of medically diagnosed migraine pain. Both companies enjoy unique differentiation in their respective markets. We anticipate that the collaboration of our companies will increase our revenues and positions in our respective marketplaces.”

Clinical analytics for TSI’s Migran-X device will provide Quture with its first application of QualOptima to medical device manufacturers. The application of Quture’s technology adds a new major health care market segment — medical device manufacturing and distribution, to Quture’s business. TSI will collaborate with Quture for continued development and testing of its FPPE-OPPE (Focused and Ongoing Professional Practice Evaluation) compliance application for proctoring physicians, dentists and other clinicians for new clinical procedures and associated medical devices.

“The vision of Quture continues to be manifested in new market segments for potential customers in medical devices,” said Landon Feazell, Chairman & CEO of Quture. “We look forward to proving the value proposition of QualOptima for medical devices, not only hospitals and physicians. Quture is pleased to announce this agreement with Therapeutic Solutions as the first contract of its subsidiary QualVal Solutions providing consulting services bundled with our QualOptima product.”

ABOUT THERAPEUTIC SOLUTIONS, INC. (www.therapeuticsolutionsint.com)
Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X® and AMPSA CS®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X® and AMPSA CS® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today. Non-US dentists and physicians can order our AMPSA products at www.ordertsoi.com.

ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. (QUTR) is the proven and experienced clinical performance and outcomes analytics company in the United States. The vision of Quture is to connect all constituents in the global health and health care community to clinically and financially focused and sound data transformed through analytics to knowledge that empowers data-driven decisions for results-driven success. As a “Breakthrough” Application Partner of InterSystems Corporation, Quture’s technology for capturing, integrating and aggregating data on the InterSystems Enterprise platform is unequalled. The Company’s unique product QualOptima develops a second generation CLINICAL database implementing Quture’s core competence of clinical content with evidence-based metrics developed for more than 35 years. QualOptima empowers clinical performance enhancement to achieve optimal patient outcomes. Quture’s brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned to become the leading clinical knowledge company in the world. Quture International is a Nevada corporation trading under the symbol QUTR.

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.

Contact:
For Further Information:
Investor Relations
TSOI
(760) 295-7208

Mele Telitz
Director of Communications
Quture
(720) 561-9643
mele@quture.com

Read More
1px

Quture (QUTR) Announces Agreement With Alejandro Guardiola, CFA, CAIA, to Become Chief Financial Officer

Mr. Guardiola Brings His Investment and Entrepreneurial Expertise, Experience and Industry Connections to Quture’s Vision and Revenue-Based Operations

DAYTONA BEACH, FL–(Marketwired – Oct 22, 2013) – Quture International, Inc. (OTCQB: QUTR) today announced agreement with Alejandro Guardiola, MS, CFA, CAIA, to become its Chief Financial Officer immediately following filing of the Company’s 10-K. In the interim, Mr. Guardiola is serving as the primary financial advisor to Quture working with the Company’s auditors in all aspects filing. However, his focus is on examination of reported debt documentation in the Company’s previous merger with Techs Loanstar, as well as several affiliations in that merger. Ultimately, the Company intends for Mr. Guardiola to work with legal counsel to be retained upon completion of this analysis. He is already engaged in negotiations with potential joint ventures or strategic alliances of Quture and its subsidiaries. He joined Quture with a significant investment in the Company’s stock.

Mr. Guardiola first became acquainted with Quture in his previous employment with UBS Financial Services in Miami during preliminary discussions regarding potential funding of new software products, potential acquisitions, and the intention of Quture to launch a personalized medicine subsidiary. He will be responsible for leading the Company to new sources of funding for these and other products, as well as the bundled services of the newly formed consulting subsidiary QualVal Solutions. He is actively engaged in these endeavors prior to formally becoming CFO as the chief financial advisor to Quture.

“I became aware of Quture, its vision and intellectual property designed to transform health and health care to a value-, performance- and outcomes-based medical model and to a more proactive, personalized wellness model with products for providers, payers, and patients while at UBS,” said Mr. Guardiola. He added: “As my personal and professional goals shifted to align with the vision and assets of Quture, I became convinced I want to focus on the growth potential ahead for Quture I am excited to be part of this dynamic and disruptive technology, the clinical-financial knowledge it will generate and integrate into health and health care. I believe these assets can play a key role in what will become the future of health and wellness internationally. The American economy is at stake, and I believe Quture can play a significant role as a free-enterprise first mover in this space to meet these challenges. I decided to leave a very favorable position and career at UBS to pursue my interests in this exponentially growing field and, in part, to take this position with Quture.”

Alejandro Guardiola completed his Master of Science degree at Florida International University. In his 7 years as a financial advisor employed by UBS Financial Services Inc. in Miami, Florida, he was registered as an Investment Advisory Rep and Broker-Dealer Agent, was able to buy/sell securities, and was authorized to give investment advice to clients. His intensive and current knowledge of the investment banking market, his entrepreneurial expertise and interests, and investor and investment banking orientation are the fundamental skills Quture sought in its new CFO. His employment is an immediate priority as Quture becomes revenue-based, transitions into new relationships, and a role-specific, highly respected and entrepreneurial management team.

“The vision of Quture continues to be manifested in our recruitment of extraordinary talent and expertise for our new management team,” said Landon Feazell, Chairman & CEO of Quture. “We look forward to proving the value proposition of QualOptima through sales of what we believe is in the pipeline, not only for hospitals but with augmented physician strategies, products and services. As we move into additional customer constituencies and rapid scalability of our products and services, I am personally and professionally proud that Alejandro chose Quture, especially since he has intimate knowledge and understanding of our Company through preliminary presentations of the strategic implementation of our Business and Marketing Plans.”

Mr. Guardiola concluded: “I like following my own investments and investment advice. The future of quality in health and health care is synonymous with our corporate strategies and intellectual property, and the name Quture expresses our confidence in that future.”

ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. (QUTR) is the proven and experienced clinical performance and outcomes analytics company in the United States. The vision of Quture is to connect all constituents in the global health and health care community to clinically and financially focused and sound data transformed through analytics to knowledge that empowers data-driven decisions for results-driven success. As an Application Partner of InterSystems Corporation, Quture’s technology for capturing, integrating and aggregating data on the InterSystems Enterprise platform is unequalled. The Company’s unique product QualOptima develops a second generation CLINICAL database implementing Quture’s core competence of clinical content with evidence-based metrics developed for more than 35 years. QualOptima empowers clinical performance enhancement to achieve optimal patient outcomes. Quture’s brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned to become the leading clinical knowledge company in the world. Quture International is a Nevada corporation trading under the symbol QUTR.

This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.

Contact:

For Further Information
Infinity Advisors
Mark Kroeger
(239) 495-6125

Mele Telitz
Director of Communications
Quture
(720) 561-9643
mele@quture.com

Read More